Our Unique Data
Historically, it had been difficult to obtain specific patient-level usage data in the oncology marketplace because most of the products were administered directly by the oncologist rather than dispensed through a pharmacy. Understanding the usage of a product by specific diagnosis, line of therapy, by stage of disease and by regimen is now possible by electronically harvesting oncology care information through IntrinsiQ’s IntelliDose clinical software.
Actual usage data confers a number of important advantages:
Actual clinical data, not survey data
Survey methodologies rely upon human recall for technical data streams. These methodologies are error prone when compared to actual clinical data.
Longitudinal view of physician and patient
By providing a patient and physician’s history over time, IntrinsiQ can determine length of therapy, interval length, switching characteristics, and identify practice patterns of physician “user” vs. “non-users”.
Unparalleled data quantity
With over 16,000 patient and over 120,000 drug administrations per month, the depth pf the data is without compare. The quantity allows for analysis of tumors with smaller levels of patient incidence and for analysis of latter lines of therapy where patient sampling can be difficult using other methods.
Swift turnaround time
IntrinsiQ’s data are transmitted electronically and there are no surveys to prepare. Therefore, our data is ready for viewing approximately twenty days after the end of a month. Some investigations can even be done on a weekly basis.